A putative sirolimus (rapamycin) effector protein

Biochem Biophys Res Commun. 1994 Aug 30;203(1):1-7. doi: 10.1006/bbrc.1994.2140.

Abstract

Sirolimus (rapamycin), a new immunosuppressive drug, inhibits proliferation of a wide spectrum of T and B cells. The immunosuppressive mechanism of sirolimus is still unclear. We recently isolated a membrane associated protein with an apparent molecular weight of 210 kDa, p210, from cultured Molt 4 cells and BJAB cells and from normal human T cells using an affinity matrix method. The p210 binds to sirolimus:FKBP12 complex, but only at background levels to FKBP12 alone, to FK506:FKBP12 complex, or sirolimus-biotin alone. Among the sirolimus analogs tested, the binding ability of p210 to drug:FKBP12 complexes correlates with the immunosuppressive activity of the drugs, suggesting that p210 is the sirolimus effector protein.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • B-Lymphocytes / metabolism
  • Base Sequence
  • Carrier Proteins / isolation & purification
  • Carrier Proteins / metabolism*
  • Cell Line
  • Cells, Cultured
  • Chromatography, Affinity
  • DNA Primers
  • Glutathione Transferase / isolation & purification
  • Heat-Shock Proteins / isolation & purification
  • Heat-Shock Proteins / metabolism*
  • Humans
  • Immunosuppressive Agents / metabolism*
  • Molecular Sequence Data
  • Molecular Weight
  • Polyenes / metabolism*
  • Polymerase Chain Reaction
  • Recombinant Fusion Proteins / isolation & purification
  • Recombinant Proteins / isolation & purification
  • Recombinant Proteins / metabolism
  • Sirolimus
  • T-Lymphocytes / metabolism*
  • Tacrolimus / metabolism*
  • Tacrolimus Binding Proteins
  • Tumor Cells, Cultured

Substances

  • Carrier Proteins
  • DNA Primers
  • Heat-Shock Proteins
  • Immunosuppressive Agents
  • Polyenes
  • Recombinant Fusion Proteins
  • Recombinant Proteins
  • Glutathione Transferase
  • Tacrolimus Binding Proteins
  • Sirolimus
  • Tacrolimus